/LNSR
LNSR Stock - LENSAR, Inc.
Healthcare|Medical - DevicesNASDAQ
$12.01+0.00%
+$0.00 (+0.00%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.53
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.93
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $13.21
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LNSR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.89 – $12.13
TARGET (TP)$13.81
STOP LOSS$11.05
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.66
52W High$17.31
52W Low$7.25
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $53.49M | $42.16M | $35.36M | $34.46M | $26.38M |
| Gross Profit | $25.85M | $21.11M | $19.95M | $17.83M | $14.07M |
| Gross Margin | 48.3% | 50.1% | 56.4% | 51.8% | 53.4% |
| Operating Income | $-10,665,000 | $-12,229,000 | $-20,177,000 | $-19,652,000 | $-18,502,000 |
| Net Income | $-31,404,000 | $-14,383,000 | $-19,914,000 | $-19,601,000 | $-19,774,000 |
| Net Margin | -58.7% | -34.1% | -56.3% | -56.9% | -75.0% |
| EPS | $-2.73 | $-1.31 | $-1.96 | $-2.10 | $-1.81 |
Company Overview
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LNSRBeat Rate
44%
Last 18 quarters
Avg Surprise
-157.0%
EPS vs Estimate
Beats / Misses
8/10
Last 12 quarters
Latest EPS
$-0.31
Q4 2025
EPS Surprise History
Q1 24
-59.1%
$-0.35vs$-0.22
Q2 24
+32.1%
$-0.19vs$-0.28
Q3 24
-82.8%
$-0.53vs$-0.29
Q4 24
+55.2%
$-0.13vs$-0.29
Q1 25
-794.4%
$-1.61vs$-0.18
Q2 25
-1446.7%
$-2.32vs$-0.15
Q3 25
-87.5%
$-0.15vs$-0.08
Q4 25
-210.0%
$-0.31vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.10 | $-0.31 | -210.0% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.08 | $-0.15 | -87.5% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.15 | $-2.32 | -1446.7% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.18 | $-1.61 | -794.4% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.29 | $-0.13 | +55.2% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.29 | $-0.53 | -82.8% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.28 | $-0.19 | +32.1% | ✓ BEAT |
Q1 2024 | Mar 4, 2024 | $-0.22 | $-0.35 | -59.1% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.34 | $-0.23 | +32.4% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.35 | $-0.81 | -131.4% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.27 | $-0.40 | -48.1% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $0.25 | $-0.24 | -196.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.62 | $-0.39 | +37.1% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.72 | $-0.67 | +6.9% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.88 | $-0.67 | +23.9% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.60 | $-0.41 | +31.7% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.59 | $-0.65 | -10.2% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.59 | $-0.47 | +20.3% | ✓ BEAT |
Frequently Asked Questions about LNSR
What is LNSR's current stock price?
LENSAR, Inc. (LNSR) is currently trading at $12.01 per share. The stock has moved +0.00% today.
What is the analyst price target for LNSR?
No analyst price targets are currently available for this stock.
What sector is LENSAR, Inc. in?
LENSAR, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is LNSR's market cap?
LENSAR, Inc. has a market capitalization of $0.14 billion, making it a small-cap company.
Does LNSR pay dividends?
No, LENSAR, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANIK
Anika Therapeutics, Inc.
$9.57
Mkt Cap: $0.1B
ARAY
Accuray Incorporated
$0.91
Mkt Cap: $0.1B
AVR
Anteris Technologies Global Corp.
$4.94
Mkt Cap: $0.2B
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$8.12
Mkt Cap: $0.1B
CRDF
Cardiff Oncology, Inc.
$2.57
Mkt Cap: $0.2B
MXCT
MaxCyte, Inc.
$1.50
Mkt Cap: $0.2B
OWLT
Owlet, Inc.
$14.05
Mkt Cap: $0.2B
PROF
Profound Medical Corp.
$7.63
Mkt Cap: $0.2B
RPID
Rapid Micro Biosystems, Inc.
$3.15
Mkt Cap: $0.1B
TLSI
TriSalus Life Sciences, Inc.
$7.42
Mkt Cap: $0.2B
Explore stocks similar to LNSR for comparison